logo

Arrowhead Pharmaceuticals Inc. (ARWR)



Trade ARWR now with
  Date
  Headline
9/6/2018 7:31:46 AM Arrowhead Presents New ARO-HBV Clinical Data Showing HBsAg Reductions At World Gastroenterologists Summit
8/31/2018 7:30:55 AM Arrowhead Completes Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease
8/1/2018 7:41:05 AM Arrowhead Pharmaceuticals Earns $10 Mln Milestone Payment From Amgen
6/29/2018 7:34:41 AM Arrowhead Presents New Clinical Data On ARO-AAT At Alpha-1 National Education Conference
6/27/2018 7:34:04 AM Arrowhead Gets Positive EMA Opinion On Orphan Designation For ARO-AAT For Congenital Alpha-1 Antitrypsin Deficiency
6/18/2018 7:31:59 AM Arrowhead Completes Enrollment In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease
5/30/2018 7:38:24 AM Arrowhead Completes Enrollment In Single Dose Portion Of Phase 1/2 Study Of ARO-HBV
5/21/2018 7:35:46 AM Arrowhead Presents New Preclinical Data On ARO-ENaC For Treatment Of Cystic Fibrosis
5/14/2018 7:33:47 AM Arrowhead Doses First Hepatitis B Patients In Multiple Dose Portion Of Phase 1/2 Study Of ARO-HBV
3/28/2018 7:32:22 AM Arrowhead Pharmaceuticals Announces Multiple Presentations At The International Liver Congress
3/27/2018 7:30:43 AM Arrowhead Begins Dosing In Phase 1/2 Study Of ARO-HBV For Chronic Hepatitis B
3/12/2018 7:30:57 AM Arrowhead Commences Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease